
A Neapolitan neonatologist used AI to write a 1.5M-word Italian-language textbook in five months. OmniNeo hit the Top Grossing chart on 0 ratings, but didn't break out.
What it is. An Italian-language textbook, drug handbook, quiz, and AI tutor for Italian neonatologists and NICU nurses, at €6.99 a month or €69.99 a year, with AI credits sold separately.
Why it took off. It didn't really. The Italian Medical Top Grossing chart has a very low bar, and annual plans are expensive. A few annual purchases in the days right after the free trial ran out were enough to push it onto the chart. Ratings stayed at 0, and Google Play has only 10+ downloads.
CHow you could approach it. Only suits someone who already works in the specialty: pick a specialty where local-language resources are scarce, use AI to draft quick-reference cards, reference values, and quizzes based on national guidelines, publicly log corrections, sell annual access on a website, and recruit through your own peers and department. Treat it as a side business.
Est. monthly revenue (App Store) under $1KWe estimated this from its chart ranks and rating growth across storefronts, calibrated against verified revenue; typical error is 2–3x. Read it as a tier, not an exact number.
- Data (updated daily) · First launched 2026-09-14 · Italy rating 0 · Charting in 11-20 storefronts 1
iOS · best category chart rank · by store Data 2026-10-30 → 2026-11-20 (22 days, 13 observations). Lower rank is higher; gaps mean it wasn't charted that dayiOS · Ratings · Italy Data 2026-10-30 → 2026-11-20 (22 days, 13 observations). Apple doesn't publish download counts; rating growth is a proxy for downloads.
OmniNeo is an Italian-language NICU textbook and quick-lookup app, most likely built by a frontline neonatologist at a hospital in Naples who used Claude alone to write the content across 21 chapters. It has 0 ratings, yet reached as high as #20 on the Italian Medical Top Grossing chart. This piece explains how much that rank is really worth, how one person produced all that content, and which parts are worth learning and which are not.
The Oct 28 update log
The OmniNeo website has a "What changed" page listing 53 updates by date. The Oct 28 entry from 2026 is labeled "Correzione" (correction). It says that the citations in the four chapters on infection, lung ultrasound, the heart, and blood were "checked one by one on PubMed. Those that didn't match real literature were removed, inaccurate ones were corrected, and figures without a source were replaced with verified data or deleted."
This update shows how the product was built. Look back through the log: in 2026, from Jun 1 to 8, a single week added 7 new chapters on endocrinology, perinatal medicine, metabolic nutrition, nephrology, gastroenterology, procedures and surgery. Each chapter has theory, a bedside cheat sheet, reference values and a quiz. One person can't write that fast, so the content was mass-generated with AI, and the author then went back and removed the "invented literature" one entry at a time.
The person behind it is listed on the App Store as the seller CIRO BARONE. The privacy policy reads "Ciro Barone, as a natural person, data controller of the OmniNeo project," and the Facebook page is located in Portici, next to Naples. At the Betania Gospel Hospital in Naples, the neonatal intensive care unit has a doctor named Ciro Barone, a pediatrician and neonatologist who has also co-authored Italian neonatology papers. Same name, same city, same specialty: the developer is very likely this frontline doctor (inferred, the official site doesn't say so directly).
What it sells and how it charges
OmniNeo is aimed at Italian neonatologists, pediatricians and NICU nurses. It includes 21 clinical chapters, a neonatal and pediatric drug handbook, lactation medication guidance, tools such as gas, bilirubin and growth charts, a nurse section, a weekly step-by-step case, a podcast, and an AI tutor built on Claude that can read images and PDFs. The official site claims "over 1.5M words, 265 genetic diseases."
| Tier | Pricing | What you get |
|---|---|---|
| Free | €0 | Full respiratory chapters, all cheat-sheet tools, the complete drug handbook, 20 questions a day |
| Trial | 15 days free on sign-up, no card required | Everything in Pro, plus 20 AI messages; invite a colleague for 15 more days |
| Pro | €6.99/month, €69.99/year | All 21 chapters, unlimited quizzes, monthly AI credits |
| AI point packs | €1.99/200, €3.99/500, €6.99/1000 | 10 credits per question, +5 credits with an image, +40 credits with a PDF |
(Official pricing page, November; annual prices from the Italian-storefront App Store in-app purchase list)
It repeatedly states it is "not a medical device": no dosage calculator, no prescriptions, and the AI is only called a "study assistant." This wording is meant to sidestep the EU Medical Device Regulation (MDR). Payments run through Stripe on the web and RevenueCat in the app (per the privacy policy). Sign-up, trials and pricing all live on the web, and the app is mostly an entry point.
0 ratings, and how it got onto the Top Grossing chart at #20
Start with its trajectory on the Italian App Store chart:
| Date | Position |
|---|---|
| 10-30 | Medical Top Grossing #64 |
| 10-31 to 11-03 | Sliding down daily: 108, 140, 163, 186 |
| 11-04 to 11-07 | Not on any chart |
| 11-08 to 11-18 | Medical Top Free #126–200, on and off |
| 11-19 | Medical Top Grossing #20 |
(App Store Italy, Medical category chart, 10-28 to 11-19)
This isn't "parked on Top Grossing." It's two spikes. Top Grossing reflects revenue from the last few days. A day with a few payments that doesn't continue after that produces exactly this shape.
The Italian Medical Top Grossing bar is also low. On 11-19 the top 60 included several apps with only 0 to 1 ratings: MesDICOM at #15, Seizly at #24, and a canine anatomy 3D app at #27 (App Store Italy, 11-19). Based on downloads and chart position, OmniNeo's iOS monthly revenue is roughly $134, with a range of $33–172 (estimate). One €69.99 annual subscription is about half that figure, so a handful of annual subscriptions or credit packs would be enough to chart (inferred).
The timing fits too. The iOS version launched in Sep 14, and the first chart run came in Oct 30, right when people who signed up in the first days hit the end of their 15 + 15-day trial (inferred). Before the second chart run, the Nov 14 1.4.7 version added "discount and new feature push notifications," but I couldn't find what discount was offered. Unverified.
The other numbers are small: the iOS rating has stayed at 0 since launch; the Google Play version has only 10+ downloads (Play page, November); the website isn't in the global top 1M sites; and on X nobody has mentioned it in the last 90 days, with no press coverage. How many people pay through Stripe on the web isn't visible from outside. That's the only place more revenue could be hiding.
Where users come from: mostly the founder himself
The acquisition channels visible are all run by the author, and they are small:
- Self-made content: Instagram @omnineo.it posts one reel a week, labeled "AI-generated content"; the Oct 23 reel got 6 likes. Breathing-animation lessons on YouTube get 4 to 33 views each. There's a podcast, "OmniNeo in cuffia," on Spotify.
- Invite to extend trial: invite a colleague and the trial goes from 15 days to 30 days.
- Retention: the sign-up page checks the newsletter box by default. A new case goes out every Monday morning, a paper every week, and push notifications were added in November.
- Department and peers: at sign-up you can optionally enter your medical association number and province, and the example shows NA (Naples) first. The earliest users were most likely his own colleagues and peers (inferred).
- App Store search: the subtitle is "Neonatologia e prontuario" (neonatology and drug handbook), and there are almost no direct competitors in Italian (inferred).
No Meta ads were found (not searched exhaustively, so it doesn't prove none were run).
Who is competing for the same users
| Competitors | Scale | How OmniNeo compares |
|---|---|---|
| NEOFARM SIN (Italian Society of Neonatology) | 7 ratings on the iOS Italy storefront | Official neonatal drug handbook, members-only, drugs only |
| UpToDate, OpenEvidence, AMBOSS | Thousands to over ten thousand ratings on the US store | English, general medicine, paid for by hospitals or institutions; no Italian neonatology-specific content |
| Mediately Farmaci, iFarmaci | 6,271 / 990 ratings on the Italy store, Medical Top Grossing #2 / #13 | General Italian drug handbooks; iFarmaci was also built by an Italian doctor on his own, which already proved that "doctor builds an app and charges for it" works |
| MediSearch AI | 109 ratings on the Italy store, Medical Top Grossing #4 | General medical AI search |
| NeoNatologyApp, PediAid, NeoBili Pro and others | 1 to 11 ratings each | A batch of doctor-built neonatal tools that appeared over 2026 years; English, single-function |
(App Store ratings by storefront and the Italy Medical Top Grossing chart, 11-19)
There really is no commercial product in Italian that combines neonatal textbooks, drugs, quizzes, AI and nursing content, and OmniNeo has taken that gap. The problem is the gap is small: Italy's NICU doctors and nurses together are estimated at only a few thousand people (estimate), and the author already holds the "hospital doctor" credential.
Worth stealing
- Industry insiders using AI to write specialist textbooks in a local language: the content moat comes from national guidelines, the local language, and the author's clinical identity. In the log he deliberately puts Italian sources first; for example, hypoglycemia is written to the Italian Society of Neonatology's recommendations from 2025, and US practice is listed only as "practice outside Italy." Global big players won't go down to this depth of localization.
- Publicly logged corrections: a single changelog page records which day which new guideline was applied, what changed, and which mismatched citations were removed. For doctors this builds more trust than the words "AI-powered," and it's a ready-made answer to AI hallucination.
- The regulatory wording: repeatedly state that it is not a medical device, perform no dosage calculation, issue no prescriptions, and present the AI only as a study assistant. This wording can be copied directly.
- Revenue structure: free trial without a card, trial extension through invites, metered AI credits sold on top of the subscription, questions with PDFs priced higher to pass model costs to heavy users. Most payment is collected on the web, reducing platform fees.
- The same template transfers: in 2026, Jul 31, the author also launched two Italian-language question-bank apps at the same time, one for driving licenses and one for yacht licenses, both as one-time purchases. The domain is omni-test.it, suggesting he meant from the start to build a platform for "anything you can test on." Neonatology is just the part he knows best.
If it were you
C. Worth learning from, not worth chasing. OmniNeo itself hasn't broken out; both chart appearances are spikes from a few annual subscriptions. Its most valuable asset is the author's clinical credential and department network, which followers can't copy. Each "minor language × specialty" pool holds only a few thousand people.
- Who it suits: doctors, nurses or pharmacists who already work in a specialty, or who have a partner in that field willing to sign their name and review content. Best in a language big global companies don't bother with (Italian, Polish, Dutch, Portuguese and similar), aiming for side-income cash flow.
- Who it doesn't suit: anyone without a medical background who wants to mass-produce medical content with AI to sell. One wrong item costs trust and creates legal risk, and the author himself had to go back and delete invented citations one by one. Also not for anyone who wants to build it big: a few thousand people per country per specialty sets the ceiling.
- How to do it: pick a specialty you use every day that has poor local-language resources. Build the three things you look up most: cheat sheets, reference values and quizzes, written to national guidelines with a source on every item. Give away the drug handbook and reference tools for free, and put the full textbook and AI tutor behind an annual subscription. Collect payment on the web and use the app only as an entry point. Publish the changelog from day one.
- How to get users: don't rely on Instagram and YouTube. OmniNeo gets only a few to a few dozen interactions per post. What works is the author's own peer network: his department, groups of residents and nurses, society annual meetings, and casually mentioning it while teaching trainees. You can copy the "invite a colleague for 15 extra days" approach. Then try one path OmniNeo hasn't tried: having a department or hospital buy several seats at once.
- When to move before it's too late: there's no rush; demand for specialist textbooks won't vanish overnight. But set a line for yourself: if fewer than 50 paying users after 3 months, stop at side-project scale and stop adding features. OmniNeo, six months in, already has forums, slide generation, a PDF workspace and an Apple Watch timer, yet its user base is still very small.
- What would prove me wrong: before 2027 March, if OmniNeo reaches more than 50 ratings on the Italy store or holds a steady spot in the top 30 of Medical Top Grossing; or if the Italian Society of Neonatology or a hospital adopts it collectively. That would show that "doctor plus AI writing specialist textbooks in the mother tongue" can be a real business even in a pool of a few thousand, and that this playbook is worth copying into other specialties and languages.
Research notes: competitor table, acquisition evidence, full research report
- Competitors
Name Where Launched Scale How it differs from this one NEOFARM SIN (Italian Society of Neonatology) iOS 2021-01 7 ratings on the iOS Italy store; members-only Official drug handbook, drugs only; OmniNeo is an open, all-in-one product with textbooks, quizzes, AI and nursing content UpToDate / Lexidrug / UpToDate Expert AI iOS 2011 / 2009 / 2026-04 587 / 6,170 / 2,871 ratings on the US store; single digits to 25 on the Italy store English, all-specialty, institutional subscription; no deep Italian neonatal content OpenEvidence iOS 2024-08 US store rating 12,247 Free English all-specialty medical AI; OmniNeo's pitch is native-language specialty textbooks, with AI as a bonus AMBOSS iOS 2017-02 US store 13,967 rating, Italy store 237; Italy Medical Top Grossing #51 All-specialty knowledge base + question bank, no Italian neonatal content MediSearch AI iOS 2023-12 Italy store 109 rating, Medical Top Grossing #4 General medical AI search; OmniNeo is specialty textbooks + quick reference Mediately Farmaci / iFarmaci iOS 2019 / 2009 Italy store 6,271 / 990 ratings, Top Grossing #2 / #13 Italian all-specialty drug handbook; OmniNeo only covers neonatal and pediatric, plus textbooks and quizzes Gomella's Neonatology / Neonatal Formulary(Skyscape) iOS 2021 / 2024 US 36 / 0 ratings English textbook e-books; OmniNeo is in Italian, updated continuously to guidelines, with AI Neonatal Guide(Cape Town Neonatal Consultancy) iOS 2021-01 US store 1 rating, $24.99 one-time purchase Also a specialty handbook written by a doctor, but English and one-time purchase; OmniNeo is Italian subscription NeoMate / neonatology.app Other Early / unknown Free Free English calculators; OmniNeo deliberately skips dose calculation and focuses on textbooks and learning - Where users come from
- Verified Instagram / Facebook / YouTube / Spotify self-made content: IG @omnineo.it posts weekly AI-labeled reels (10-23 has 6 likes); FB page Omnineo (Portici); YouTube breathing-technique lessons get 4–33 views each; Spotify has the podcast OmniNeo in cuffia
- Verified Invite rewards extend the trial: Website: 15 days free trial, inviting a colleague adds 15 more days, no card required
- Verified Newsletter / push / weekly content retention: Newsletter is pre-checked on the signup page; 1.4.7 (11-14) added discount pushes; weekly cases, literature reviews and reels
- Inferred Word of mouth among colleagues and hospital circles: The author is likely an NICU doctor at Betania Hospital in Naples; the signup page has an optional medical council registration number, with the example province NA listed first
- Inferred App Store search: Subtitle is Neonatologia e prontuario; almost no Italian-language competitors
- Inferred Paid ads: No record in the metaads library (this library doesn't track it, so no record doesn't mean no ads)
OmniNeo (ios_6795620609) research report
Bottom line: It hasn't really taken off. OmniNeo is an Italian-language NICU reference and learning platform, most likely built by a Naples neonatologist (probably alone) with AI. The web version launched at 2026-05, the iOS app on 2026-09-14. The signal when I first found it was "0 rating yet ranked #20 on Italy's Medical Top Grossing chart," but that chart has a very low bar: a few annual subscriptions or credit packs can push you up, and you fall off within days. On Google Play it has 10+ installs, one Instagram reel has 6 likes, each YouTube video gets 4–33 views, and there's no press or discussion on X. What's worth watching is the approach: a doctor plus AI producing 1.5M words of native-language specialty content, sold as a subscription. The user base is nowhere near big yet.
1. What it is
- Product: A "textbook + quick reference + AI tutor" for Italian neonatologists, pediatricians and NICU nurses. Content includes 21 clinical chapters (each with theory, bedside quick-reference cards, reference values and quizzes), neonatal and pediatric drug handbooks, drugs in breastfeeding, tools for blood gases, bilirubin and growth percentiles, a nursing section with 15 modules, a Claude-based AI tutor (reads images and PDFs), plus a PubMed library, Desk (a PDF reading and writing workspace), slide generation, the podcast "OmniNeo in cuffia", weekly cases, a forum, feature voting, and an Apple Watch delivery room timer (Apgar reminders, a 30-second resuscitation reminder, 3:1 metronome) (website omni-test.it/, App Store description).
- Pricing: Free signup gives 15 days of full-feature trial, no card required; inviting friends adds 15 more days. Pro is €6.99/month or €69.99/year; AI credit packs are €1.99/200, €3.99/500 and €6.99/1000, with each question costing 10 credits (https://omni-test.it/prezzi.html; Italy store in-app purchase list). Web payments run through Stripe, in-app purchases through RevenueCat (privacy policy omni-test.it/privacy_it.html).
- Positioning: Repeatedly states it is "not a medical device", does no dose calculation and issues no prescriptions, deliberately sidestepping MDR regulation.
- Developer: The App Store seller is an individual, CIRO BARONE. The privacy policy says "Ciro Barone, as a natural person, is the data controller for the OmniNeo project", and the support email on Play is [email protected]. The Facebook page "Omnineo" is located in Portici (next to Naples). At the Neonatal Intensive Care Unit (UOC Terapia Intensiva Neonatale e Neonatologia) of Ospedale Evangelico Betania in Naples there is a Dott. Ciro Barone, specializing in pediatrics and neonatology, registered with the Naples medical council (https://www.ospedalebetania.org/professionisti/ciro-barone/), and he has co-authored Italian neonatology papers (the Pediatr Pulmonol LISA study, PubMed 43018973). Inference: the developer is most likely this frontline neonatologist, with high probability, though the website doesn't state it directly.
- Two other apps from the same developer (both listed on the same day as 2026-07-31): Patente Guida: Quiz AM, A e B (driving-license question bank, 0 rating) and Patente Nautica Vela e Motore (boating-license question bank, 1 ratings). Both are one-time purchases with no ads (iTunes lookup). The domain omni-test.it also suggests he first aimed for an "all-in-one test prep" platform, with neonatology as the area he knows best.
2. What the data actually shows
Italy App Store chart trajectory (appstore library chart_rank / app_day, cc=it)
| Date | chart | Rank |
|---|---|---|
| 10-28, 10-29 | — | Not charted |
| 10-30 | Medical Top Grossing | 64 |
| 10-31 | Medical Top Grossing | 108 |
| 11-01 | Medical Top Grossing | 140 |
| 11-02 | Medical Top Grossing | 163 |
| 11-03 | Medical Top Grossing | 186 |
| 11-04 to 11-07 | — | Not on any chart |
| 11-08 to 11-18 | Medical Top Free | 126–200 (on and off) |
| 11-19 | Medical Top Grossing / Top Free | 20 / 137 |
- The recall claimed it "stayed on the Top Grossing chart", which is inaccurate. It was actually two spikes: 10-30 it entered at #64, then slid down day by day and dropped off on day 5; then on 11-19 it suddenly jumped to #20. Top Grossing is weighted by recent revenue, and this shape is typical of "a few payments came in on one day, with no sustained income afterward".
- The Italy Medical Top Grossing chart has a very low bar. On the same day (11-19), the top 60 included MesDICOM (15,0 rating), Seizly (24,1 rating), Complete Canine Anatomy 3D (27,1 rating) and ICU Advantage Rapid Reference (59,0 rating). A 0-rating app making the top 20 is common on this chart (appstore library v_chart, 2026-11-19).
- Revenue scale: The app library estimates iOS monthly revenue at about $134 (range $33–172), with monthly downloads around 840 (model estimate, stringers App library ios_6795620609). A single €69.99 annual subscription equals about half the estimated monthly revenue, so one annual sale can easily produce a spike (inferred).
- The 11-19 spike may be tied to push notifications: Version 1.4.7 (11-14) had just added "discount and new feature push notifications" (App Store update notes). The timing lines up, but I did not find a specific discount campaign, so this is unverified.
- The rating count has stayed at 0 since launch, with no sign of downloads growing.
- Google Play: it.omnineo.app, 10+ downloads, 2026-11-11 updates (Google Play page). The recall card's "1K+ installs on Play" is wrong. It isn't in the googleplay library, which suggests it never charted.
- Website: omni-test.it is not in Tranco's top 1M (no record in the traffic library).
- Conclusion: Both money and users are small. The main front is likely the web plus Stripe (pricing, signup and trial all happen on the web, and the app is a wrapper), so the App Store shows only the tip of the iceberg. The number of paying users on the web is unknown.
3. Competitors
| Competitors | Platform | Launched | Scale | How OmniNeo differs |
|---|---|---|---|---|
| NEOFARM SIN (Italian Society of Neonatology) | iOS / Android / web | 2021-01 | iOS Italy ratings: 7 (appstore library) | Official neonatal drug handbook, only for SIN members; drugs only, no textbooks, quizzes or AI |
| UpToDate / UpToDate Lexidrug / UpToDate Expert AI | iOS / web | 2011 / 2009 / 2026-04 | US store 587 / 6,170 / 2,871 ratings; Italy store 25 / 6 / 6 | Institutional subscription, English, all-specialty; expensive, paid for by hospitals; no Italian neonatal specialty content |
| OpenEvidence | iOS / web | 2024-08 | US store rating 12,247 | Free doctor AI Q&A, English, all-specialty; OmniNeo's AI is a bonus, its pitch is Italian specialty textbooks |
| AMBOSS | iOS / web | 2017 | US store 13,967 rating; Italy store 237, Medical Top Grossing #51 in Italy | All-specialty knowledge base + question bank, in German and English; no Italian neonatal depth |
| MediSearch AI | iOS | 2023-12 | Italy store 109 rating, Medical Top Grossing #4 in Italy | General medical AI search; a counterpart on the same chart that makes money from AI subscriptions |
| Mediately Farmaci | iOS / Android | 2019 | Italy store 6,271 rating, Medical Top Grossing #2 | Italian all-specialty drug handbook (AIFA labels); OmniNeo only covers neonatal and pediatric drugs, plus textbooks |
| iFarmaci(Andrea Isidori) | iOS | 2009 | Italy store 990 rating, Top Grossing #13 | Also a drug reference built by an Italian doctor on their own; Italy already has precedent for "doctor builds an app and charges for it" |
| Gomella's Neonatology / Neonatal Formulary(Skyscape) | iOS | 2021 / 2024 | US 36 / 0 ratings | E-book editions of classic English textbooks, sold per book; OmniNeo is in Italian, continuously updated, with quizzes and AI |
| Neonatal Guide(Cape Town Neonatal Consultancy) | iOS | 2021 | US store 1 ratings, $24.99 | A paid English handbook by a South African neonatologist; same approach, targeting the English-language market |
| NeoNatologyApp / PediAid / NeoBili Pro / NewIQ, etc. | iOS | 2026-03 to 2026-08 | 1–11 ratings each | Over 2026 years a batch of doctor-built neonatal tools (calculators, bilirubin, blood gas) appeared, all in English and all single-purpose |
| NeoMate (Incubate, NHS ecosystem) | Android / iOS | Early on | Free | Free dosing and infusion calculators from the UK NHS |
| neonatology.app | Web | Unknown | Unknown | English web tools with 60+ neonatal calculators and clinical guides, free |
| Italian paper textbooks (e.g., neonatology textbooks edited by De Curtis and others) | Other | Years | Unknown | Traditional textbooks; OmniNeo claims "handbooks update by edition, OmniNeo updates to guidelines" |
Bottom line: there is no product in Italian that covers neonatal textbooks, drugs, quizzes, AI and nursing together. The official NEOFARM SIN only does drugs and is members-only; the big international players are all English-language general references. OmniNeo owns a very narrow gap — "Italian × neonatal × doctors and nurses" — but that gap itself is small.
4. Growth tactics (where users come from)
| Channel | Evidence | Confirmed? |
|---|---|---|
| Self-made content on Instagram / Facebook / YouTube / Spotify | IG @omnineo.it posts a reel every week (tagged "AI content"); the one for 10-23 got only 6 likes. FB page "Omnineo" (Portici). YouTube @OmniNeo-it: the ventilation animation course gets 4–33 views per video. Spotify has the podcast "OmniNeo in cuffia". The website homepage shows "this week's reel" and an AI-generated promo video. | Confirmed, but very small reach |
| Invite rewards | "15 + 15 days free: invite a colleague and get 15 more days" (website homepage) | Confirmed |
| Retention tools: newsletter / push / weekly content | Newsletter opt-in is pre-ticked on the signup page; 1.4.7 added discount pushes (App Store release notes); weekly cases, weekly literature review, weekly reel (website). | Confirmed |
| Word of mouth among colleagues and hospital circles | The author works in a NICU in Naples (inferred). The signup page has an optional field for "medical council registration number + province code" for license verification; NA (Naples) is listed first in the example. | Inferred, unverified |
| App Store search | The category subtitle is "Neonatologia e prontuario", which has almost no competitors in Italian. | Inferred |
| Paid ads | No ads from OmniNeo or omni-test.it appear in the metaads library (but that library only tracks advertisers found through keyword discovery, so no results doesn't mean they aren't advertising). | Not found |
| Media, X, society endorsements | x-radar: 0 posts in the last ~90 days. Search engines show no media coverage; the SIN website doesn't mention it. | None |
5. Why it could "chart" (not why it's trending)
- Low bar to chart: in the Medical Top Grossing chart's top 60, several apps have only 0–1 ratings. A handful of annual subscriptions or credit packs can push you into the top 20 (appstore library, 2026-11-19).
- High ticket, no-card trial: €69.99/year, plus usage-billed AI credits, means one paying user is worth dozens of users of a typical utility app. After launch on 9-14, the first top-grossing spike appeared on 10-30, right when the people who signed up early hit the end of their 15 + 15-day trial. The timing matches (inferred).
- The author is inside the industry: a frontline NICU doctor writes the content and promotes it within the department. Both the target users and the source of trust are close to him (inferred).
- AI raised how much content one person can produce: from 5 through June there was a new chapter nearly every two or three days, claiming 1.5M words and 265 genetic diseases (changelog at omni-test.it/changelog.html). 10-28's own changelog admits "checked PubMed, removed citations that didn't match real literature", meaning the content was largely AI-generated and then manually cleaned of hallucinations.
6. Differentiation
- Differentiation: Italian + neonatal specialty + both doctor and nurse tracks + an all-in-one of "textbook, quick reference, quizzes, AI tutor", and it strictly follows Italian national guidelines (e.g. SIN 2025 hypoglycemia recommendations, AIFA labeling), putting "Italian sources" first (changelog 11-04). This is localization depth that big English players like UpToDate and OpenEvidence won't do, and productization that society products like NEOFARM SIN don't do.
- Is this why it "broke out"? It explains why people would pay €70/year (enough to hit the top-grossing chart), but not the scale. The audience ceiling is very low (Italian NICU medical staff are in the thousands, unverified), distribution is nearly zero, so it didn't break out; it just has sporadic payers in a small pool.
7. Visibility and copycats
- Visibility: few people know about it yet. No public revenue, no media coverage, 0 mentions on X; 10+ Play downloads; each social post gets single digits to a few dozen engagements.
- Copycats: none. In 2026 a batch of neonatal English-language mini-tools made by doctors appeared (NeoNatologyApp 2026-05, PediAid 2026-08, NeoBili Pro 2026-03, etc.), but they were independent waves of similar products, not copies of OmniNeo.
8. Takeaways
- "Industry insider + AI-written content" as a specialty subscription: a practitioner used Claude to write the volume of a specialty textbook in a few months, then added quizzes, spaced repetition, flashcards and an AI tutor, sold as an annual subscription. The content moat comes from "national guidelines + local language + the author's clinical identity", which big players won't bother with.
- The regulatory framing: repeatedly states "not a medical device", no dose calculations, no prescriptions, the AI is only called a "study assistant", and patient identifiers are stripped with regex before anything goes to the model, minimizing MDR risk. This approach can be copied directly.
- Monetization structure: no-card trial + extended trial via invites + subscription + metered AI credits (a surcharge for questions with attachments), passing model costs on to heavy users.
- Main channel is the web: web payments go through Stripe, the app is just an entry point, avoiding most of the 30% commission.
- The same template transfers: the author already used the same template for driving-license and boat-license question banks. It would also work for other specialties (anesthesia, emergency, obstetrics) or other minority languages, but each pool is small, so it suits a "one-person side-income" rather than a big business.
9. Still unclear
- Whether the developer is Dott. Ciro Barone of Betania hospital (same name, same city, same specialty, most likely, but not officially confirmed).
- How many paying users are on the web via Stripe. The App Store only shows iOS in-app purchases, and iOS is estimated at only about $134/month.
- What caused the 11-19 top-grossing spike: discount push, department-wide subscriptions, or one or two annual payments.
- Whether it's running paid ads on Meta (our ad library doesn't track it).
- Accuracy of AI-generated content: the changelog admits removing fabricated citations, so the quality risk for medical content remains.
Sources
- App Store: apps.apple.com/it/app/omnineo/id6795620609; iTunes lookup (id=6795620609, 6794028099, 6794843402, country=it)
- Website: omni-test.it/, /prezzi.html, /changelog.html, /privacy_it.html
- Google Play: play.google.com/store/apps/details?id=it.omnineo.app (10+ downloads, 2026-11-11 updates)
- Hospital page: www.ospedalebetania.org/professionisti/ciro-barone/
- Social: www.instagram.com/omnineo.it/ (reel De1xujWTucX, 6 likes), www.facebook.com/p/Omnineo-61595424563490/, www.youtube.com/@OmniNeo-it, open.spotify.com/show/7FcsDd4rF8cqX13gfmihoN
- Internal libraries: appstore (chart_rank, app_day, v_chart, app_snapshot, as of 2026-11-19), googleplay (no records), metaads (no records), traffic (no records), x-radar (0 posts), Stringers App library (estimated monthly revenue $134)